Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Primary Immune Thrombocytopenia (ITP)
NCT05279872Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Started Jan 2022; status: completed.
02
Drugs
zanubrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05279872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279872.